Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor

BMC Medical Genomics volume 7, Article number: 49 (2014) Cite this article

Abstract

Background

Cytokine-induced killer (CIK) cells are an emerging approach of cancer treatment. Our previous study have shown that CIK cells stimulated with combination of IL-2 and IL-15 displayed improved proliferation capacity and tumor cytotoxicity. However, the mechanisms of CIK cell proliferation and acquisition of cytolytic function against tumor induced by IL-2 and IL-15 have not been well elucidated yet.

Methods

CIKIL-2 and CIKIL-15 were generated from peripheral blood mononuclear cells primed with IFN-γ, and stimulated with IL-2 and IL-15 in combination with OKT3 respectively. RNA-seq was performed to identify differentially expressed genes, and gene ontology and pathways based analysis were used to identify the distinct roles of IL-2 and IL-15 in CIK preparation.

Results

The results indicated that CIKIL-15 showed improved cell proliferation capacity compared to CIKIL-2. However, CIKIL-2 has exhibited greater tumor cytotoxic effect than CIKIL-15. Employing deep sequencing, we sequenced mRNA transcripts in CIKIL-2 and CIKIL-15. A total of 374 differentially expressed genes (DEGs) were identified including 175 up-regulated genes in CIKIL-15 and 199 up-regulated genes in CIKIL-2. Among DEGs in CIKIL-15, Wnt signaling and cell adhesion were significant GO terms and pathways which related with their functions. In CIKIL-2, type I interferon signaling and cytokine-cytokine receptor interaction were significant GO terms and pathways. We found that the up-regulation of Wnt 4 and PDGFD may contribute to enhanced cell proliferation capacity of CIKIL-15, while inhibitory signal from interaction between CTLA4 and CD80 may be responsible for the weak proliferation capacity of CIKIL-2. Moreover, up-regulated expressions of CD40LG and IRF7 may make for improved tumor cytolytic function of CIKIL-2 through type I interferon signaling.

Conclusions

Through our findings, we have preliminarily elucidated the cells proliferation and acquisition of tumor cytotoxicity mechanism of CIKIL-15 and CIKIL-2. Better understanding of these mechanisms will help to generate novel CIK cells with greater proliferation potential and improved tumor cytolytic function.

Peer Review reports

Background

Cancer is still a leading cause of diseases related death all over the world. It was estimated that 7.6 million people were dead from various types of cancer in 2008, and the figure will continue to rise to 13.1 million in 2030 [1]. Fortunately, significant progress has been made to develop better approaches to prevent, diagnose and treat cancer in the past several years. These advances have made more people survive with their cancer today. However, these new approaches are not completely effective to all of cancers, and side effects were brought by some of treatments. Among these advances, immunotherapy has shown its large potential in cancer therapy. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes with a natural killer T cell phenotype, have been proven to be effective to most of tumors in vitro and in vivo [2]. CIK cells exhibit potent cytolytic activities against tumor cells with minimal adverse effects. CIK cells are prepared from peripheral blood mononuclear cells (PBMCs) by priming with IFN-γ, and maintained with monoclonal antibody against CD3 (OKT3) and interleukin-2 in the following days [3]. During the generation of CIK cells, monoclonal antibody against CD3 provided mitogenic signals to T lymphocytes. Priming with IFN-γ is to activate the monocytes which provide contact-dependent (CD58/LFA-3) and soluble (IL-12) crucial signals promoting generation of autophagy and antigen cross-presentation [4]. In following bulk culture, IL-2 promotes T cell proliferation, survival and acquisition of cytolytic effector function.

IL-15 is a cytokine which stimulate growth of NK, NKT cells and activated T lymphocytes in peripheral, and it has similar biological properties with IL-2 in innate immunity [5]. Studies have suggested that IL-15 bind to subunits of IL-2 receptor and common gamma chain [6]. Because IL-15 and IL-2 share common signaling components, they mediate a series of similar signaling events. These events include activation of the Janus kinase (Jak) and STAT pathways. The two cytokines both can facilitate the induction of tumor toxic effector T cells and proliferation of NK cells. However, IL-15 and IL-2 are differed in their cDNA/protein sequence and contribute differently to T cell-mediated immune response [6]. Although IL-2 is a growth and survival factor, it plays important role in Fas-mediated activation-induced cell death (AICD) of CD4 T cell. In contrast, IL-15 promotes the survival of T lymphocytes by inhibiting IL-2-mediated CD4+ T cell AICD [7].

In our previous study, we have shown that CIK cells stimulated with combination of IL-2 and IL-15 exhibited enhanced cytotoxic capacity against lung cancer both in vitro and in vivo. Interestingly, we found that CIK cells activated with IL-2 and IL-15 could up-regulate the expression levels of IFN-γ and TNF-α in vivo compared to CIK cell stimulated with IL-2 alone [8]. In order to identify the roles of IL-2 and IL-15 during induction of tumor toxic function of CIK cells, we performed comparative transcriptome analysis between CIK cells prepared with IL-15 and IL-2 respectively by Ion PI mRNA sequencing (RNA-seq) for the first time. The mRNAs isolated from CIKIL-15 cells and CIKIL-2 cells were transcribed into cDNAs which were applied to deep sequencing. The results of RNA-seq were analyzed by a series of bioinformatic methods including mapping, gene differential expression analysis, gene ontology (GO) and pathway analysis. Our finding will provide evidence for optimizing the CIK cell propagation strategy which produces more effective CIK cells against tumor.

Methods

Cell lines and reagents

Human lung adenocarcinoma (SPC-A-1 cells) and gastric tumor cells (BGC823) were obtained from Chinese Type Culture Collection (Shanghai, PR China). FITC conjugated anti-CD56 antibody and R-phycoerythrin conjugated anti-CD3 antibody used in identifying CIK phenotypic markers were purchased from BD Biosciences. The cell viability assay kit (Cell Counting Kit-8) was purchased from Dojindo, Molecular Technologies. Reagents for CIK cells generation including OKT3, IFN-γ, IL-2 and IL-15 were from Miltenyi Biotec. Experiments involving human peripheral blood were reviewed and approved by Bioethics Committee of Yan’an Affiliated Hospital of Kunming Medical University. Written informed consents have been given from all volunteers participated in this study.

Generation of CIKIL-2 and CIKIL-15(Standard protocols)

The Bioethics Committee of Yan’an Affiliated Hospital of Kunming Medical University has approved the investigation protocols to draw blood from healthy volunteers after written informed consent for the purposes of preparation CIK cells against tumor and deep sequencing. CIK cells were prepared from PBMCs which were isolated by standard Ficoll separation. PBMCs were cultured in RPMI 1640 growth medium at a density of 5 × 106 cells/mL. The RPMI 1640 growth medium for CIK contained 10% FBS, 2% L-glutamine and antibiotics. The generation of CIK cells was primed by adding 1000 U/mL IFN-γ on day 0 and 100 ng/mL anti-CD3 antibody and 500 U/mL IL-2 or 10 ng/mL IL-15 within the following 15 days of culture. The CIK cells were propagated every 5 days with RPMI 1640 growth medium supplemented with anti-CD3 antibody and IL-2 or IL-15 respectively [9]. The CIK cells were expanded for 15 days and analyzed every 5 days.

Cytotoxicity assay based on CCK-8

After co-culture with CIK cells for 48 hours, the cell viabilities of two tumor cells were determined by CCK-8 based methods. Briefly, 10uL of CCK-8 solution was added in each well, and the plates were incubated at 37°C for 2–4 hours. After incubation, the absorbance of each well was read by a spectrophotometer at 450 nm. Each sample for one treatment was calculated by values from 5 independent samples.

RNA extraction and quality control

Total RNA was extracted from each sample using TRIzol Reagent (Life technologies, USA) according to the protocol from manufacturer. The concentration of each sample was measured by NanoDrop 2000 (Thermo Scientific, USA). The quality was assessed by the Agilent2200 (Agilent, USA).

Whole transcriptome libraries preparation and deep sequencing

The sequencing library of each RNA sample was prepared by using Ion Total RNA-Seq Kit v2 according to the protocol provided by manufacturer (Life technologies, USA). Briefly, poly(A)-containing mRNA was purified from 5 ug total RNA with Dynabeads (Life technologies, USA). The mRNA was fragmented using RNaseIII and purified. The fragmented RNA was hybrized and ligated with Ion adaptor. The RNA fragments were reverse-transcribed and amplified to double-stranded cDNA. Then, the amplified cDNA was purified by magnetic bead based method, and the molar concentration was determined for each cDNA library. Emulsion PCR was performed using template of cDNA library. The Template-Positive Ion PITM Ion SphereTM Particles were enriched and loaded on the Ion PITM chip for sequencing.

Filtering raw reads and mapping

The raw reads ≥50 bp which passed filtering were used for mapping. We used the Masplicing as our RNA-seq data mapping analysis tool whose core program is Bowtie that can identify the exon-exon splicing immediately and accurately [10].

Identification of differentially expressed genes

We applied the DEseq to filter the differentially expressed genes for the CIKIL-15 and CIKIL-2 groups. After the statistical analysis, we selected the differentially expressed genes according to the FDR threshold (FDR < 0.05) [11].

GO analysis

GO analysis was applied to analyze the main function of the differential expression genes according to the Gene Ontology which is the key functional classification of NCBI [12, 13]. Generally, Fisher’s exact test and χ 2 test were used to classify the GO category, and the false discovery rate (FDR) was calculated to correct the P-value, the smaller the FDR, the small the error in judging the p-value [14, 15]. The FDR was defined as FDR=1− N k T , where N k refers to the number of Fisher’s test P-values less than χ 2 test P-values. We computed P-values for the GOs of all the differential genes. The significant GO terms were defined as P value <0.05 and FDR <0.05. Concerning on the treatment of GO term redundancy, we have adopted strategy of filtering out terms by picking only one from each leaf-to-root path.

Pathway analysis

Similarly, pathway analysis was used to find out the significant pathway of the differential genes according to KEGG, Biocarta and Reactome [10, 16, 17]. Still, we turn to the Fisher’s exact test and χ 2 test to select the significant pathway, and the threshold of significance was defined by P-value and FDR. The significant pathway was identified by P value <0.05 and FDR < 0.05. The enrichment was calculated like the equation above [18–20].

Gene-act-network

Use the KEGG database to build the network of genes according to the relationship among the genes, proteins and compounds in the database [21–25].

Path-act-network

KEGG database has included metabolism, membrane transport, signal transduction, cell cycle pathways and information about interactions among them. The genes we have selected may involved in two or more signaling pathways. Because of the same genes in different pathways, overlappings between pathways were obvious. We picked the genes in enriched biological pathway and used Cytoscape for graphical representations of pathways [26].

Co-expression network analysis

For each pair of genes, we calculate the Pearson Correlation and choose the significant correlation pairs (FDR < 0.01) to construct the network [27]. Within the network analysis, degree centrality is the most simplest and important measures of the centrality of a gene within a network that determine the relative importance. Degree centrality is defined as the link numbers one node has to the other [28]. Moreover, to study some properties of the networks, k-cores in graph theory were introduced as a method of simplifying graph topology analysis [29].

Quantitative reverse-transcription PCR

All the qRT-PCR involved in this study was performed on the CFX96 Touch™ (BIORAD, USA). The first strand of cDNA was synthesized with adjusted concentration of RNA, and corresponding genes were amplified by employing EVA Green Supermix. All the primers used for qRT-PCR were obtained from GeneCopoeia (USA).

Results

Enhanced cell proliferation capacity of CIKIL-15 and superior tumor toxic effect of CIK IL-2

CIK cells were generated from peripheral blood mononuclear cells of three healthy volunteers. The CIKIL-15 and CIKIL-2 cells were confirmed by flow cytometry with the phenotypes of CD3+CD56+. The results have demonstrated that the percentages of CD3+CD56+ cells were 98.80 ± 0.503% and 97.60 ± 0.603% respectively in CIKIL-2 and CIKIL-15 (Figure 1A). We determined the proliferation capacities of CIKIL-15 and CIKIL-2 by automatic cell counting. The result showed that CIKIL-15 displayed significantly higher proliferation capacity than CIKIL-2 (Figure 1B). To evaluate the tumor toxic effects of CIKIL-15 and CIKIL-2, we have chosen two types of tumor cell lines including human gastric tumor (BGC823) and human lung adenocarcinoma (SPC-A-1) as the targets in anti-tumor assay. After co-culture with CIKIL-15 and CIKIL-2 for 48 hours, the cell viabilities were measured for each type of tumor based on CCK-8 method. The results indicated that CIKIL-2 cells have shown greater cytotoxic potential against tumor than CIKIL-15 (Figure 1C). In order to investigate the distinct roles of IL-2 and IL-15 in CIK cell generation, we performed transcriptome-wide analysis of CIKIL-2 (n = 3) and CIKIL-15 (n = 3) by deep sequencing.

Figure 1
figure 1

A overview of phenotypes, functions and RNA-seq quality control of CIK IL-15 and CIK IL-2 . (A) Flow cytometric and statistical analysis of the proportion of CD3+CD56+ CIK cells. Numbers indicate the percentage of each subset. (B) Cell proliferation capacity assay of CIKIL-15 and CIKIL-2 based on automatic cell counting; (C) Detection of tumor cytotoxic effect of CIKIL-15 and CIKIL-2 against SPC-A-1 and BGC823; (D) Distribution of reads on chromosomes; (E) Percentage of mapped reads onto the regions of exons, introns, 5’-UTR, 3’-UTR, transcription start site (TSS), transcription end site (TES) and intergenic region.

Full size image

Overview of sequencing data of RNA-seq analysis

Total raw reads among the six samples ranged from 19 to 34 million. The average of the GC content is approximately 49% for each sample. By a stringent quality check, more than 95% of the reads we obtained have a quality score of ≧Q20. The sequencing quality was analyzed by using RSeQC [30]. The raw sequence data have yielded about 2.2 gigabases (GB) of data per sample. About 1.58 ± 0.48 × 107 reads (73.5% of the total raw reads) were mapped to human genome sequence in the six independent samples (Table 1) and 1.49 ± 0.48 × 107 reads (69.5% of the total raw reads) were uniquely aligned to human genome. The mapping of the reads was performed by using MapSplice. Mapped reads in six independent samples were distributed consistently on the chromosomes (Figure 1D). We found that chromosome 1 has been matched the most reads and the least reads were found in chromosome Y. In the uniquely mapped reads, more than 50% of the reads were aligned at the transcript exon, 17% at the intron regions, 13% at the UTR regions and the remaining at TES (transcription end site), TSS (transcription start site) and intergenic regions (Figure 1E). Subsequently, we analyzed the aligned reads for transcript assembly, abundance evaluation and normalization. After annotation, there were 3,6267 transcripts annotated with known function Additional file 1. In order to quantify the expression levels of the transcripts, the RNA-seq data was normalized to RPKM values.

Table 1 Statistics of raw and mapped reads from RNA-seq analysis of CIK cells stimulated by IL-15 and IL-2 respectively
Full size table

Differential gene expression profiles of CIKIL-15 and CIKIL-2and GO analysis

To characterize the functional consequences of gene expression changes induced by IL-15 and IL-2, we screened the differentially expressed genes (DEGs) between CIKIL-15 cells and CIKIL-2 cells by the following criteria: Log2FC > 1 or Log2FC < −1, FDR < 0.05 and P value < 0.05. We found 374 DEGs between CIKIL-15 and CIKIL-2 Additional file 2. Of these DEGs, 175 and 199 genes were up-regulated in CIK cells activated by IL-15 and IL-2 respectively. We used hierarchical cluster analysis to compare the DEGs between these two types of CIK cells and similarity of expression patterns of three biological replicates (Figure 2). To identify the functions of these DEGs, we performed gene ontological analysis based on GO database Additional file 3. Among these DEGs which were up-regulated in CIKIL-15, there were 11 genes involved in cell adhesion and 5 genes involved in Wnt signaling pathway (Figure 2). By analyzing the significant GO terms, we found that T cell receptor V(D)J recombination, cell adhesion and alpha-beta T cell differentiation were involved (Figure 3A). In order to target the DEGs which may cause functional changes, we screened DEGs whose GO terms were closely related with the functions of CIK cells. Based on the functional assay, CIKIL-15 cells have shown greater proliferation capacity than CIKIL-2 cells in vitro. Interestingly, we found that Wnt 4 was significantly up-regulated in CIKIL-15 compared to CIKIL-2 (Table 2). By gene ontological analysis, Wnt 4 is involved in multiple biological processes including Wnt signaling pathway, immature T cell proliferation and negative regulation of apoptosis (Table 2). Platelet-derived growth factor D (PDGFD) is a growth factor that plays an essential role in cell proliferation and survival. The expression of PDGFD is up-regulated after stimulation of IL-15. Therefore, we speculated that the enhanced proliferation capacity of CIKIL-15 may be brought by up-regulation of Wnt4 and PDGFD. Interleukin 21 receptor, which has played important role in natural killer cell activation and cytokine signaling pathway was found highly expressed in CIKIL-15. Moreover, E3 ubiquitin protein ligase (DTX4) and intercellular adhesion molecule (ICAM4) were also up-regulated in CIKIL-15. These proteins may be involved in type I interferon production and cell adhesion. Among the DEGs in CIKIL-2, there were 17 genes participated in innate immune response, 16 genes involved in cytokine-mediated signaling pathway and 12 genes involved in type I interferon signaling pathway (Figure 2). By analyzing the significant go terms, we found that type I interferon signaling pathway, cytokine-mediated signaling pathway and immune response are significant GO terms in response to stimulation of IL-2 (Figure 3B). Compared to CIKIL-15, CIKIL-2 has shown enhanced cytotoxic capacity against tumor. Consistently, we have found 3 tumor suppressive genes which were significantly up-regulated in CIKIL-2 including tumor necrosis factor ligand superfamily member 10 (TNFSF10), CD40 ligand (CD40LG) and interferon regulatory factor 7 (IRF7) (Table 3). These genes were widely involved in positive regulation of apoptotic signaling pathway, potent anti-tumor effect and promote type I interferon production. Surprisingly, we found that CD80 and its inhibitory ligand CTLA4 were co-upregulated in CIK cells after activation of IL-2. The function of CD80 is mainly involved in the costimulatory signal for T lymphocyte activation. CTLA4 functions as a negative regulator of T cell activation, which may inhibit the T cell proliferation.

Figure 2
figure 2

Clustering of differentially expressed genes in CIK IL-15 and CIK IL2 and multiple DEGs involved GO terms. The genes included for further analysis were labeled with red line by the sides of their gene symbols.

Full size image
Figure 3
figure 3

Significant gene ontology analysis of DEGs in CIK IL-15 and CIK IL-2 . (A) Significant GO terms of CIKIL-15; (B) Significant GO terms of CIKIL-2. P value < 0.01 for all significant GO terms.

Full size image
Table 2 Up-regulated genes related with functions and phenotypes of CIK IL-15
Full size table
Table 3 Up-regulated genes related with functions and phenotypes of CIK IL-2
Full size table

Pathways analysis of CIKIL-15 and CIKIL-2

To further identify the influence of DEGs on the functions of these two types of CIK cells, we performed pathway analysis of DEGs based on KEGG database using Fisher exact test Additional file 4. Among DEGs of CIKIL-15, there 5 genes participated in focal adhesion including collagen type VI alpha 3 (COL6A3), collagen alpha-2(VI) chain (COL6A2), collagen alpha-1(VI) chain (COL6A1), Platelet-derived growth factor D (PDGFD) and Myosin light chain kinase family member 4 (MYLK4) (Figure 4A). Surprisingly, 3 genes coding collagens were involved in this pathway which may be related with enhanced cell proliferation capacity of CIKIL-15. In CIKIL-2, the results indicated that 13 genes participated in cytokine-cytokine receptor interaction (Figure 4B). Of these genes, IL-4 and CXCL10 were newly identified DEGs that may contributed to tumor suppression. Subsequently, we have built the pathways interaction network to perform deep analysis. Through analyzing the interactions among the significant pathways, it was obvious Wnt signaling pathway, focal adhesion and cytokine-cytokine receptor interaction were the most important pathways involved in the function of CIKIL-15 and CIKIL-2 (Figure 4C). Because these three pathways located at the centers of each clusters and showed the most interactions with their surrounding pathways (the most arrows toward them). The results suggested that Wnt 4 signaling pathway and focal adhesion be the key biological events of CIKIL-15 cell proliferation, and cytokine-cytokine receptor interaction be the dominant element in CIKIL-2 cells in acquisition of tumor cytotoxic capacity. This evidence indicated that DEGs involved in these three pathways may play important roles in the distinct functions of CIKIL-15 and CIKIL-2.

Figure 4
figure 4

Pathway enrichment analysis of DEGs based on KEGG. (A) Enriched pathways in CIKIL-15; (B) Enriched pathways in CIKIL-2; (C) Pathways interaction network of CIKIL-15 and CIKIL-2, Red circles represent enriched pathways in CIKIL-15; Green circle represent enriched pathways in CIKIL-2.

Full size image

Differentially expressed genes act network

After functional analysis, it is important to explore the relationships among these DEGs. According to KEGG database, we built the act network of genes based on the relationships between them including activation\binding, expression, inhibition and compound. In this gene interaction network, CXCL10, CXCL9, CCL22, GLI2, WNT4, CD80 and CTLA4 were in involved in pathways which previously mentioned including Wnt signaling pathway, Cytokine-cytokine receptor interaction and T cell signaling (Figure 5). In Figure 5, we showed that GLI2 (Zinc finger protein) functioned as transcription factor which involved in the expression of protein Wnt 4 in CIKIL-15. Again, the interaction between CD80 and CTLA-4 has been highlighted in CIKIL-2. After stimulation of IL-2, CD80 were up-regulated and interacted with CD28 providing costimulation signal for T cell activation and proliferation. However, negative feedback has been turned on through up-regulating the expression of CTLA4 which bound to CD80 providing inhibitory signal instead of CD28. Moreover, we also have noticed that CXCL10, CCL22 and CXCL9 were associated with CCR1. The association among these genes may be related with anti-tumor activity and CIK cell recruitment.

Figure 5
figure 5

Gene Act network analysis. Red circles represent up-regulated genes in CIKIL-15; Green circles represent up-regulated genes in CIKIL-2.

Full size image

Gene co-expression network

Alternatively, we performed the gene co-expression network analysis between DEGs in CIKIL-15 and CIKIL-2 to highlight groups of DEGs in synergy which may participate in biological processes resulted in phenotypic changes [31, 32]. Among DEGs of CIKIL-15, we showed that the expression levels of IL21R (Interleukin 21 receptor), ENPP3 (Ectonucleotide pyrophosphatase/phosphodiesterase 3) and TXNIP (Thioredoxin interacting protein) were positively correlated (Pearson’s r = 0.99), and mainly involved in immune response (Figure 6A). Moreover, we also found a group of genes that related with immune response including IFI44 (Interferon-induced protein 44), FOXP3 (Forkhead box P3), IF44L (Interferon-induced protein 44-like), LY9 (T-lymphocyte surface antigen Ly-9) and IFI27 (Interferon, alpha-inducible protein 27) in CIKIL-15 (Figure 6A). It was obvious that a cluster genes related with cell proliferation and apoptosis including PDGFD (Platelet-derived growth factor D), PHLDA1 (PHLDA1 protein), DSCC1 (Sister chromatid cohesion protein), S100A8 (Protein S100-A8), DST (Bullous pemphigoid antigen 1) and EIF2AK2 (EIF2AK2 protein) were correlated in CIKIL-15 (Figure 6A). In CIKIL-2, three pairs of genes with similar expression profiles were found to be involved in type I interferon signaling pathway (MX1/USP18; MX2/OAS1; IFT1/IFT3) (Figure 6B). Interestingly, the expression pattern of T cell activation negative regulator Foxp3 was correlation with the expression of IL-17 receptor B in CIKIL-2 (Figure 6B).

Figure 6
figure 6

Gene co-expression network analysis. (A) CIKIL-15; (B) CIKIL-2; Degree in different color is defined as the link numbers one node has with the other. The Pearson Correlation of each pair of genes were calculated from these three independent samples.

Full size image

Validation of representative genes by qRT-PCR

We have examined the expression profiles of DEGs which were referred in Table 2 and Table 3. The results of qRT-PCR have indicated that the expression profiles of DEGs in CIKIL-15 and CIKIL-2 were consistent with RNA-seq except for TNFSF10 (Figure 7). Notably, the expression level of Wnt 4 in CIKIL-15 was over 3 fold of those in CIKIL-2. However, TNFSF10 in CIKIL-2 were slightly higher than CIKIL-15 (p>0.05). Therefore, TNFSF10 may not be a contributor of enhanced tumor toxic function of CIKIL-2.

Figure 7
figure 7

qRT-PCR validation of relative expression levels of representative DEGs. (A) DEGs in CIKIL-15; (B) DEGs in CIKIL-2; the expression levels of corresponding genes were normalized by β-actin. The results were means and SEMs, representative of nine independent samples. (P < 0.05 in all DEGs except TNSF10).

Full size image

Discussion

Although clinical trials of CIK cells in cancer therapy were widely performed in China, fewer studies on molecular mechanism of their anti-tumor function were observed [33, 34]. The pioneering work of CIK cells was performed by Schmidt-Wolf from Stanford. The authors indicated that CIK cells were a subset of non-MHC-restricted T cells expressing both CD3 and CD56, and CIK cells showed potent cytotoxicity against a variety of tumor cells [2]. The efficiency of CIK cells preparation is dependent on T cell proliferation and cytolytic activity against tumor. To generate CIK cells with high quality, cytokines such as IL-1, IL-7, IL-15 and IL-12 have been employed instead of IL-2 or in combination with IL-2 [4]. Of these cytokines, IL-15 is widely tested in CIK cells preparation against several tumor cells. In this study, the results have indicated that CIKIL-15 exhibit enhanced proliferation capacity than CIKIL-2, whereas, CIKIL-2 showed more efficient cytotoxic effect against tumor cells than CIKIL-15. Consistently, the results from transcriptome analysis have shown corelationship with their functional characteristics.

IL-15 is a pleiotropic cytokine which promote T cells and NK cells proliferation and survival [35, 36]. To better elucidate the mechanism of increased proliferation capacity induced by IL-15, we have found that Wnt 4 and PDGFD which were correlated with cell proliferation were up-regulated in CIKIL-15. Wnt signaling pathway is widely involved in cell proliferation and differentiation [37]. It has been reported that Wnt agonist promoted mouse muscle cell proliferation, and specific silencing RNA knockdown of Wnt 4 significantly reduced muscle cell proliferation [38]. Moreover, study showed that the expression of Wnt 4 was required for proliferation of cells in mouse coelomic epithelium [39]. By pathway interaction analysis, we have found that Wnt signaling pathway is located at the center of the network, which got the most interactions with other pathways. Therefore, we suggested that Wnt signaling be one of the most important pathways which contributed to the improved proliferation capacity of CIKIL-15. Except for Wnt 4, PDGFD is also a proliferation promoting factor which regulates several cellular processes including cell proliferation, apoptosis and transformation [40]. Over-expression of PDGFD in mouse or human breast cancer cell significantly increased cell proliferation while silencing PDGFD expression decreased proliferation and increased apoptosis [41]. Studies have indicated that PDGFD promoted cell proliferation by increasing DNA binding capacity of NF-κB and down-regulation of PDGFD inhibit tumor invasion through inactivation of Notch-1 and NF-κB signaling [42]. Therefore, the up-regulation of Wnt 4 and PDGFD may be responsible for enhanced cell proliferation of CIKIL-15.

Additionally, we also have found important evidence which may inhibit the proliferation of CIKIL-2. By differentiated expressed genes and gene act network analysis, we found that CTLA4 and CD80 were up-regulated in CIKIL-2. These two proteins can interact with each other to provide inhibitory signal during T cell activation [43]. In the generation of CIKIL-2, OKT3 and IL-2 were sustainedly presented in the culture system. However, IL-2 mediated activation-induced cell death (AICD) occurred during the following culture [7]. Consistently, our previous phenotypic study of CIKIL-2 have showed that the cells subset of CD3+CD28+ was increasing in the first several days while significantly decreased since the 7th day of culture (Data not shown). These results demonstrated that the interaction between CTLA4 and CD80 may lead to inactivation of CD3+CD28+ T cell and inhibit proliferation of CIKIL-2. The inhibitory signal from ligation of CTLA4 to CD80 is the negative feedback to IL-2 stimulation of CIK cells. Comprehensively, not only up-regulated Wnt 4 and PDGFD but also activation inhibitory signal from CTLA4 and CD80 in CIKIL-2 has resulted in the enhanced proliferation capacity of CIKIL-15. We suggest that supplement with cytokines or mAb which down-regulates the inhibitory signal from CTLA4 and CD80 facilitate proliferation of CIKIL-2 production.

The most important of characteristic of CIK cell is cytolytic activity against tumor. In vitro, CIKIL-2 cells have shown more efficient tumor cytotoxicity than CIKIL-15. The expression of CD40LG and IFR7 were up-regulated in CIKIL-2. CD40LG, which is the ligand of CD40, has shown great potentials in cancer therapy [44]. It has been reported that CD40 is expressed in nearly all B cell malignancy and many solid tumors [45]. The ligation of CD40 on the surface of tumor cells inhibits the growth of tumor and induces apoptosis [46]. Besides CD40LG, IFN-β has also been found to play critical role in anti-tumoral immune response [47]. Interestingly, Moschonas has indicated that stimulation of CD40 by its ligand has promoted the expression of IFN-β through the binding IRF7 to its promoter. IRF7 is a transcriptional factor which regulates the expression of type I interferon [48]. Silencing of IRF7 pathways in breast cancer accelerated bone metastasis through immune escape [49]. Thus CD40LG and IFR7 may work synergically to improve the tumor cytotoxic effect of CIKIL-2.

On the other hand, the expression of DTX4 was up-regulated in CIKIL-15 which positively regulated the production of type I interferon through NLRP4 [50]. Moreover, the expression of IL-21R whose ligand is involved in natural killer cell was also increased in CIKIL-15. Paradoxically, the up-regulation of PDGFD in CIKIL-15 not only could promote the proliferation of CIKIL-15 cells but also promote tumor cells survival through cell and cell interaction in tumor cytotoxic assay. PDGFs are composed of four different polypeptide chains (PDGF A-D). It has been reported that PDGFD was deregulated in most of human malignancies with up-regulated expression in solid tumors [51]. The factor interacts with PDGFR-β and activates downstream signaling phosphatidylinositol 3-kinase (PI3K)/AKT, resulted in tumor progression. Moreover, Li et al. reported that PDGFD is a potent transformation growth factor for NIH/3 T3 which increased the cell proliferation rate [52]. We suggested that up-regulated PDGFD is a double-edged sword in CIKIL-15. Because it favored the proliferation of CIKIL-15 cells during preparation, while it may also promoted the survival and proliferation of tumor cells when CIK cells were in contact with tumor cells.

Conclusions

In this study, deep sequencing was performed to analyze the different gene expression profiles of CIKIL-2 and CIKIL-15 for the first time. By advanced bioinformatic analysis of DEGs, we found that cell proliferation promoting function was dominant in CIKIL-15 involving Wnt signaling pathway and focal cell adhesion. In CIKIL-2, type I interferon signaling pathway and cytokine-cytokine receptor interactions were dominant. Through our findings, we have preliminarily elucidated the cells proliferation and acquisition of tumor cytotoxicity mechanism of CIKIL-15 and CIKIL-2. Better understanding of these mechanisms will help to generate novel CIK cells with greater proliferation potential and improved tumor cytolytic function.

References

  1. Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ: AACR Cancer Progress Report 2013. Clin Cancer Res. 2013, 19 (20 Suppl): S4-S98.

    PubMed  Google Scholar 

  2. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991, 174 (1): 139-149.

    Article  CAS  PubMed  Google Scholar 

  3. Linn YC, Hui KM: Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010, 2010: 435745.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Jiang J, Wu C, Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013, 11: 83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fehniger TA, Caligiuri MA: Interleukin 15: biology and relevance to human disease. Blood. 2001, 97 (1): 14-32.

    Article  CAS  PubMed  Google Scholar 

  6. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994, 180 (4): 1395-1403.

    Article  CAS  PubMed  Google Scholar 

  7. Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001, 14 (2): 105-110.

    CAS  PubMed  Google Scholar 

  8. Wei C, Wang W, Pang W, Meng M, Jiang L, Xue S, Xie Y, Li R, Hou Z: The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol. 2014, 35 (3): 1997-2007.

    Article  CAS  PubMed  Google Scholar 

  9. Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P: The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012, 14 (1): 91-103.

    Article  CAS  PubMed  Google Scholar 

  10. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, Mieczkowski P, Grimm SA, Perou CM, MacLeod JN, Chiang DY, Prins JF, Liu J: MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010, 38 (18): e178.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Anders S, Huber W: Differential expression analysis for sequence count data. Genome Biol. 2010, 11 (10): R106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gene Ontology Consortium: The Gene Ontology (GO) project in 2006. Nucleic Acids Res. 2006, 34 (Database issue): D322-D326.

    Article  Google Scholar 

  13. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25 (1): 25-29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Benjamini YHY: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995, Series B (57): 289-300.

    Google Scholar 

  15. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A: False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005, 21 (13): 3017-3024.

    Article  CAS  PubMed  Google Scholar 

  16. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28 (1): 27-30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, Lewis S, Birney E, Stein L: Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2005, 33 (Database issue): D428-D432.

    Article  CAS  PubMed  Google Scholar 

  18. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004, 32 (Database issue): D277-D280.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yi M, Horton JD, Cohen JC, Hobbs HH, Stephens RM: WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics. 2006, 7: 30.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R: A systems biology approach for pathway level analysis. Genome Res. 2007, 17 (10): 1537-1545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jansen R, Greenbaum D, Gerstein M: Relating whole-genome expression data with protein-protein interactions. Genome Res. 2002, 12 (1): 37-46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Li C, Li H: Network-constrained regularization and variable selection for analysis of genomic data. Bioinformatics. 2008, 24 (9): 1175-1182.

    Article  CAS  PubMed  Google Scholar 

  23. Wei Z, Li H: A Markov random field model for network-based analysis of genomic data. Bioinformatics. 2007, 23 (12): 1537-1544.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang JD, Wiemann S: KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor. Bioinformatics. 2009, 25 (11): 1470-1471.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wang M, Verdier J, Benedito VA, Tang Y, Murray JD, Ge Y, Becker JD, Carvalho H, Rogers C, Udvardi M, He J: LegumeGRN: a gene regulatory network prediction server for functional and comparative studies. PLoS One. 2013, 8 (7): e67434.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13 (11): 2498-2504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Prieto C, Risueno A, Fontanillo C, De las Rivas J: Human gene coexpression landscape: confident network derived from tissue transcriptomic profiles. PLoS One. 2008, 3 (12): e3911.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Barabasi AL, Oltvai ZN: Network biology: understanding the cell’s functional organization. Nat Rev Genet. 2004, 5 (2): 101-113.

    Article  CAS  PubMed  Google Scholar 

  29. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL: Hierarchical organization of modularity in metabolic networks. Science. 2002, 297 (5586): 1551-1555.

    Article  CAS  PubMed  Google Scholar 

  30. Wang L, Wang S, Li W: RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012, 28 (16): 2184-2185.

    Article  CAS  PubMed  Google Scholar 

  31. Villa-Vialaneix N, Liaubet L, Laurent T, Cherel P, Gamot A, SanCristobal M: The structure of a gene co-expression network reveals biological functions underlying eQTLs. PLoS One. 2013, 8 (4): e60045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kumari S, Nie J, Chen HS, Ma H, Stewart R, Li X, Lu MZ, Taylor WM, Wei H: Evaluation of gene association methods for coexpression network construction and biological knowledge discovery. PLoS One. 2012, 7 (11): e50411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY, Ye YB: Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS One. 2013, 8 (7): e69044.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Yang Z, Zhang Q, Xu K, Shan J, Shen J, Liu L, Xu Y, Xia F, Bie P, Zhang X, Cui Y, Bian XW, Qian C: Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One. 2012, 7 (9): e44802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J: Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med. 2002, 196 (7): 935-946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Zhang J, Sun R, Wei H, Tian Z: Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica. 2004, 89 (3): 338-347.

    CAS  PubMed  Google Scholar 

  37. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature. 2005, 434 (7035): 843-850.

    Article  CAS  PubMed  Google Scholar 

  38. Tsaousi A, Williams H, Lyon CA, Taylor V, Swain A, Johnson JL, George SJ: Wnt4/beta-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ Res. 2011, 108 (4): 427-436.

    Article  CAS  PubMed  Google Scholar 

  39. Chassot AA, Bradford ST, Auguste A, Gregoire EP, Pailhoux E, de Rooij DG, Schedl A, Chaboissier MC: WNT4 and RSPO1 together are required for cell proliferation in the early mouse gonad. Development. 2012, 139 (23): 4461-4472.

    Article  CAS  PubMed  Google Scholar 

  40. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH: Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta. 2010, 1806 (1): 122-130.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat. 2011, 126 (1): 15-25.

    Article  CAS  PubMed  Google Scholar 

  42. Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, Sarkar FH: Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67 (23): 11377-11385.

    Article  CAS  PubMed  Google Scholar 

  43. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP: CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 1999, 162 (10): 5813-5820.

    CAS  PubMed  Google Scholar 

  44. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG: Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001, 19 (13): 3280-3287.

    CAS  PubMed  Google Scholar 

  45. Vonderheide RH: Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007, 13 (4): 1083-1088.

    Article  CAS  PubMed  Google Scholar 

  46. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, Young LS: CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol. 2000, 20 (15): 5503-5515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Nunez NG, Andreani V, Crespo MI, Nocera DA, Breser ML, Moron G, Dejager L, Libert C, Rivero V, Maccioni M: IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012, 72 (3): 592-603.

    Article  CAS  PubMed  Google Scholar 

  48. Moschonas A, Ioannou M, Eliopoulos AG: CD40 stimulates a “feed-forward” NF-kappaB-driven molecular pathway that regulates IFN-beta expression in carcinoma cells. J Immunol. 2012, 188 (11): 5521-5527.

    Article  CAS  PubMed  Google Scholar 

  49. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Moller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012, 18 (8): 1224-1231.

    Article  CAS  PubMed  Google Scholar 

  50. Cui J, Li Y, Zhu L, Liu D, Songyang Z, Wang HY, Wang RF: NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat Immunol. 2012, 13 (4): 387-395.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang Z, Kong D, Li Y, Sarkar FH: PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets. 2009, 10 (1): 38-41.

    Article  PubMed  Google Scholar 

  52. Li H, Fredriksson L, Li X, Eriksson U: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 2003, 22 (10): 1501-1510.

    Article  CAS  PubMed  Google Scholar 

Pre-publication history

Download references

Acknowledgements

We thank Dr. Zhu Xiaoyun for his constructive suggestions to this study. This work is supported by grants from National Natural Science Foundation of China (No. 81160267 and 81360245) and grants from the “Special and Joint Program” of Yunnan Province Science and Technology Department & Kunming Medical University.

Author information

Author notes

    Authors and Affiliations

    1. Yan’an Affiliated Hospital, Kunming Medical University, Kunming, 650051, Yunnan, People’s Republic of China

      Wenju Wang, Mingyao Meng, Yayong Zhang, Chuanyu Wei, Yanhua Xie, Lihong Jiang, Chunhui Wang, Weiwei Tang, Xingfang Jin, Zongliu Hou & Ruhong Li

    2. Kunming Medical University, Kunming, 650050, Yunnan, People’s Republic of China

      Fang Yang

    3. Novel Bioinformatics Co., Ltd, Shanghai, China

      Dai Chen & Jie Zong

    Authors
    1. Wenju Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Mingyao Meng
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yayong Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Chuanyu Wei
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yanhua Xie
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Lihong Jiang
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Chunhui Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Fang Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Weiwei Tang
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Xingfang Jin
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Dai Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Jie Zong
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. Zongliu Hou
      View author publications

      You can also search for this author in PubMed Google Scholar

    14. Ruhong Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Zongliu Hou or Ruhong Li.

    Additional information

    Competing interests

    The authors declare that they have no competing interests.

    Authors’ contributions

    ZLH and RHL conceived and designed the study. WJW, MYM and YYZ performed the experiments. WJW, DC and JZ analyzed the data. CHW and WWT contributed reagents/material. CYW, YHX and LHJ interpreted the data and wrote the paper. FY and XFJ revised the manuscript. All authors read and approved the final manuscript.

    Wenju Wang, Mingyao Meng contributed equally to this work.

    Electronic supplementary material

    Authors’ original submitted files for images

    Rights and permissions

    Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

    The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

    To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

    The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, W., Meng, M., Zhang, Y. et al. Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor. BMC Med Genomics 7, 49 (2014). https://doi.org/10.1186/1755-8794-7-49

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/1755-8794-7-49

    Keywords

    BMC Medical Genomics

    ISSN: 1755-8794

    Contact us